Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P07741

UPID:
APT_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
P07741; G5E9J2; Q3KP55; Q68DF9

BACKGROUND:
Adenine phosphoribosyltransferase, encoded by the gene with accession number P07741, is pivotal in the purine salvage pathway, transforming adenine into AMP. This process is less energy-intensive than synthesizing AMP de novo, highlighting the enzyme's importance in cellular energy management.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Adenine phosphoribosyltransferase could open doors to potential therapeutic strategies for conditions like Adenine phosphoribosyltransferase deficiency, where enzyme malfunction leads to severe metabolic disorders, including urolithiasis and renal failure.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.